TransMedics' stock pops after organ-transplant company's 'blockbuster' third-quarter results
By Eleanor Laise
Company boosts full-year sales outlook as it launches transplant-aviation business
TransMedics Group Inc. shares (TMDX) jumped more than 40% premarket on Tuesday after the company reported third-quarter results reflecting growing demand for its organ-transplant services and raised its full-year revenue outlook.
The company late Monday reported a net loss of $25.42 million, or 78 cents per share, compared with a loss of $7.43 million, or 25 cents per share, in the year-earlier period. The FactSet consensus was a loss of 16 cents per share. Revenue totaled $66.43 million, up from $25.68 million and ahead of the FactSet consensus of $49.2 million.
TransMedics raised its full-year sales guidance to a range of $222 million to $230 million, up from prior guidance of $180 million to $190 million.
Sales growth was driven by increasing demand for the company's Organ Care System products, which use a technology designed to better preserve and assess donor organs and reduce the number of unused organs, according to TransMedics. The system, which focuses on lung, heart and liver transplants, maintains the organs in a living, functioning state.
The net loss in the quarter was driven primarily by $29.2 million in acquisition-related costs, TransMedics said. The company recently closed its acquisition of Summit Aviation as it prepares to launch a new transplant aviation business.
Oppenheimer analysts on Tuesday called the results a "blockbuster" quarter for TransMedics, saying the company's strategy of offering an organ-transplant logistics and service one-stop shop, "while bumpy short-term, should yield dividends long-term." The company's organ-care system, the analysts wrote, "represents a disruptive technology that could potentially revolutionize solid organ preservation and transport" by narrowing the gap between demand and supply of donor organs and expanding the pool of usable organs.
More than 100,000 people in the U.S. are on the national transplant waiting list, according to federal government data.
TransMedics shares are down 35% in the year to date, while the S&P 500 has gained 13.7%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-07-23 0852ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks